Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study

Sharifa Nasreen,1,2 Andrew J Calzavara,2 Maria E Sundaram,1,2 Shannon E MacDonald,1,2,3 Christiaan H Righolt,5 Menaka Pai,6 Thalia S Field,7 Lily W Zhou,7,8 Sarah E Wilson,1,9 Jeffrey C Kwong1,2

ABSTRACT

Objective The objective of this study was to estimate background rates of selected thromboembolic and coagulation disorders in Ontario, Canada.

Design Population-based retrospective observational study using linked health administrative databases. Records of hospitalisations and emergency department visits were searched to identify cases using International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Canada diagnostic codes.

Participants All Ontario residents.

Primary outcome measures Incidence rates of ischaemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage, deep vein thrombosis, pulmonary embolism, idiopathic thrombocytopaenia, disseminated intravascular coagulation and cerebral venous thrombosis during five prepandemic years (2015–2019) and 2020.

Results The average annual population was 14 million with 51% female. The mean annual rates per 100 000 population during 2015–2019 were 127.1 (95% CI 126.2 to 127.9) for ischaemic stroke, 22.0 (95% CI 21.6 to 22.3) for intracerebral haemorrhage, 9.4 (95% CI 9.2 to 9.7) for subarachnoid haemorrhage, 86.8 (95% CI 86.1 to 87.5) for deep vein thrombosis, 63.7 (95% CI 63.1 to 64.3) for pulmonary embolism, 6.1 (95% CI 5.9 to 6.3) for idiopathic thrombocytopaenia, 1.6 (95% CI 1.5 to 1.7) for disseminated intravascular coagulation, and 1.5 (95% CI 1.4 to 1.6) for cerebral venous thrombosis. Rates were lower in 2020 than during the prepandemic years for ischaemic stroke, deep vein thrombosis and idiopathic thrombocytopaenia. Rates were generally consistent over time, except for pulmonary embolism, which increased from 57.1 to 68.5 per 100 000 between 2015 and 2019. Rates were higher for females than males for subarachnoid haemorrhage, pulmonary embolism and cerebral venous thrombosis, and vice versa for ischaemic stroke and intracerebral haemorrhage. Rates increased with age for most of these conditions, but idiopathic thrombocytopaenia demonstrated a bimodal distribution with incidence peaks at 0–19 years and >60 years.

Conclusions Our estimated background rates help contextualise observed events of these potential adverse events of special interest related to COVID-19 vaccine.

INTRODUCTION

As COVID-19 vaccines are rapidly being licensed and used in mass immunisation programmes worldwide, postmarketing safety surveillance is essential to identify rare adverse events and maintain vaccine confidence.1 In March 2021, there had been...
reports of serious thrombotic events from the UK, the European Union and Scandinavian countries related to the ChAdOx1-S (AstraZeneca) vaccine.\textsuperscript{1} The European Medicines Agency (EMA) at that time reviewed seven cases of disseminated intravascular coagulation and 18 cases of cerebral venous thrombosis (including nine deaths) following vaccination.\textsuperscript{2} These events occurred predominantly in females aged <55 years. Based on pre-COVID-19 rates of these two rare conditions, the EMA’s safety committee noted that observed events among vaccinated individuals were higher than expected for that age group (expected vs observed within 14 days of vaccination in those aged <50 years: 1 vs 5 for disseminated intravascular coagulation, and 1.35 vs 12 for cerebral venous thrombosis), and they recommended close safety monitoring and further analysis.\textsuperscript{2} A causal relationship between these two rare events and the vaccine was neither proven nor ruled out. However, the overall number of thromboembolic events after vaccination was not deemed to be higher than expected.\textsuperscript{2} The EMA mandated that information on the thrombotic events be added to AstraZeneca vaccine’s summary of product characteristics and package leaflets.

This situation underscores the invaluable role of knowing background rates in vaccine safety signal assessments.\textsuperscript{3} Without background rates, the occurrence of adverse events in vaccinated individuals could be misinterpreted as a vaccine safety signal.\textsuperscript{4–6} However, background rates may vary by several factors, including geography, sex, age and calendar time.\textsuperscript{3,4}

Following a risk assessment based on available data on the reported events in Europe, Health Canada described in public messaging that a combination of thrombosis and thrombocytopenia had been observed very rarely following vaccination with the AstraZeneca COVID-19 vaccine, although there was no overall increased risk of thrombosis and that the benefits of the vaccine outweighed the risks.\textsuperscript{7} In response to the safety signal in Europe, Health Canada also updated the product monograph for AstraZeneca to include information on the reported rare events.\textsuperscript{8} In its first statement on AstraZeneca vaccine, Canada’s National Advisory Committee on Immunisation (NACI) initially recommended its use in adults aged 18–64 years due to insufficient evidence on efficacy in older adults available at that time, although the recommendation was later expanded to include adults aged ≥65 years.\textsuperscript{9} There was considerable variability across Canadian provinces and territories in regards to the populations offered AstraZeneca vaccine. Following a review of more detailed risk information on vaccine-induced immune thrombotic thrombocytopenia, NACI ultimately recommended that AstraZeneca should not be used in individuals<30 years, and should only be offered if mRNA vaccines are contraindicated or inaccessible.\textsuperscript{10}

There is a lack of Canadian data on recent background rates of potential thromboembolic and coagulation disorder adverse events of special interest (AESI) that might inform ongoing safety surveillance of AstraZeneca’s COVID-19 vaccine and others. Therefore, we sought to estimate background rates of hospitalisations and emergency department visits for selected thromboembolic and coagulation disorders during five prepandemic years (2015–2019) and 2020 in Ontario, Canada.

**METHODS**

We conducted a population-based retrospective observational study using health administrative databases from Ontario, Canada. These datasets were linked using unique identifiers and analysed at ICES. We searched records of hospitalisations and emergency department visits to identify cases of ischaemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage, deep vein thrombosis, pulmonary embolism, idiopathic thrombocytopenia, disseminated intravascular coagulation, and cerebral venous thrombosis using diagnostic codes from the International Statistical Classification of Diseases and Health Problems, 10th Revision, Canada (ICD-10-CA)\textsuperscript{11} (online supplemental table S1). Where available, we used codes that have been previously validated.\textsuperscript{12–16}

We used the Canadian Institute for Health Information (CIHI) Discharge Abstract Database (DAD) and CIHI’s National Ambulatory Care Reporting System to identify hospitalisations and emergency department visits, respectively. We included inpatient cases where an ICD-10-CA code of interest was indicated as being present on admission and of primary relevance to the stay (as opposed to being listed as a secondary diagnosis, comorbidity or part of the medical history). We included emergency department visits where a code of interest was present in any diagnosis field. We counted only new cases after a 365-day period without the same condition (ie, group of codes) (online supplemental table S1). Information on age and sex were obtained from Ontario’s Registered Persons Database, which contains all Ontarians registered under the Ontario Health Insurance Plan.

**Statistical analysis**

For each AESI, we calculated annual incidence rates per 100000 population by age and sex during each of five prepandemic years (2015–2019) and 2020, and also the overall mean annual incidence for 2015–2019. Similarly, we calculated annual and overall mean (for 2015–2019) incidence rates separately by sex, by age group (0–19, 20–29, 30–39, 40–49, 50–59, 60–69, 70–79 and ≥80 years), and by sex and age group. To examine seasonality, we calculated monthly averages (per 30 days) for 2015–2019. We used Statistics Canada Census and intercensal population estimates as denominators. The 95% CIs were calculated using a gamma distribution.\textsuperscript{17}

**Patient and public involvement**

There was no direct interaction with patients in this study and no direct patient involvement in the design or conduct of this study.
We also observed an increasing trend in the incidence of pulmonary embolism starting before the pandemic that warrants further investigation to elucidate the cause. However, it is possible that the observed trend may have resulted from changes in clinical or coding practices over time and does not reflect a true increase in the underlying disease pattern. Lack of recent data on the trends of pulmonary embolism incidence precluded other rate comparisons.

Our estimated rates of stroke and the observed higher rates in males are comparable to previously reported global rates. However, higher stroke incidence was reported in females aged 18–44 years than their male counterparts (incidence rate ratio of females compared with males ranging from 1.14 to 1.93) in the Netherlands during 1998–2010. Another study in China also reported a higher age-adjusted incidence of stroke in females than males (309 vs 280 per 100 000 population) in 2014. Our crude rates of ischaemic stroke and intracerebral haemorrhage during 2015–2017 were approximately 1.5–2 times the age- and sex-standardised rates during the same period in a previous study in Ontario. However, that study included only the first-ever episode whereas we included episodes occurring after a 365-day period.

There are limitations in the estimated rates of deep vein thrombosis in recent years. Lower rates reported in older studies are likely because they included only the first incident case, whereas we included recurrent cases at least 1 year apart. On the other hand, the overall rate of deep vein thromboses in our study is much lower than the adult hospitalisation rate reported in the USA during 2007–2009. The higher USA rates are likely because that study included multiple hospitalisations in a year, and they also included cases that developed during hospitalisation from other conditions whereas our study looked at deep vein thrombosis on admission only.

There is a lack of data on the incidence of disseminated intravascular coagulation, a systemic coagulopathy that is always secondary to an underlying clinical condition, such as sepsis, malignancy, trauma, acute pancreatitis, burns or obstetric complications. As such, studies often estimate the burden of disseminated intravascular coagulation for the underlying conditions separately. The incidence of the first episode of disseminated intravascular coagulation in ICU admitted adult patients in the USA was 18.6 per 100 000 person-years in 2010, which is far higher than the rates we have estimated.

The estimated overall incidence of cerebral venous thrombosis in our study is similar to the overall hospitalisation rate of 1.75 per 100 000/year in Norway during 2011–2020 and 1.32 per 100 000/year in Finland during 2005–2014. However, these rates are much higher than previously reported rates of 0.1–0.5 per 100 000 population/year. These differences are primarily attributable to increased use of routine vascular neuroimaging. Females in the USA had a higher incidence than males (2.69–3.02/100 000 in females vs 0.68–1.68/100 000 in males) during 2006–2016; females aged
### Table 1

Mean background rates of hospitalisations and emergency department visits for selected thromboembolic and coagulation disorders in Ontario from 2015 to 2019

<table>
<thead>
<tr>
<th>Age group, years</th>
<th>Incidence per 100,000 population (95% CI)</th>
<th>Ischaemic stroke</th>
<th>Intracerebral haemorrhage</th>
<th>Subarachnoid haemorrhage</th>
<th>Deep vein thrombosis</th>
<th>Pulmonary embolism</th>
<th>Idiopathic thrombocytopaenia</th>
<th>Disseminated intravascular coagulation</th>
<th>Cerebral venous thrombosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All ages</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All ages</td>
<td>127.07 (126.24 to 127.91)</td>
<td>21.96 (21.62 to 22.31)</td>
<td>9.43 (9.20 to 9.66)</td>
<td>86.79 (86.10 to 87.48)</td>
<td>63.68 (63.09 to 64.27)</td>
<td>6.08 (5.90 to 6.26)</td>
<td>1.55 (1.46 to 1.65)</td>
<td>1.52 (1.43 to 1.62)</td>
<td></td>
</tr>
<tr>
<td>0–19</td>
<td>1.78 (1.57 to 2.00)</td>
<td>1.01 (0.86 to 1.19)</td>
<td>0.68 (0.56 to 0.83)</td>
<td>4.22 (3.91 to 4.56)</td>
<td>2.25 (2.02 to 2.50)</td>
<td>6.17 (5.79 to 6.58)</td>
<td>0.45 (0.35 to 0.57)</td>
<td>1.12 (0.96 to 1.30)</td>
<td></td>
</tr>
<tr>
<td>20–29</td>
<td>4.68 (4.27 to 5.13)</td>
<td>2.28 (1.99 to 2.60)</td>
<td>1.80 (1.55 to 2.09)</td>
<td>26.66 (25.65 to 27.70)</td>
<td>18.83 (17.98 to 19.71)</td>
<td>2.99 (2.66 to 3.36)</td>
<td>0.96 (0.77 to 1.17)</td>
<td>1.30 (1.09 to 1.55)</td>
<td></td>
</tr>
<tr>
<td>30–39</td>
<td>13.07 (12.35 to 13.83)</td>
<td>3.91 (3.52 to 4.33)</td>
<td>3.96 (3.57 to 4.39)</td>
<td>53.73 (52.25 to 55.23)</td>
<td>31.34 (30.21 to 32.49)</td>
<td>3.76 (3.38 to 4.17)</td>
<td>1.07 (0.87 to 1.30)</td>
<td>1.62 (1.38 to 1.90)</td>
<td></td>
</tr>
<tr>
<td>40–49</td>
<td>36.88 (35.66 to 38.14)</td>
<td>8.27 (7.70 to 8.88)</td>
<td>7.90 (7.34 to 8.49)</td>
<td>80.49 (78.68 to 82.34)</td>
<td>45.68 (44.32 to 47.07)</td>
<td>3.78 (3.39 to 4.19)</td>
<td>1.04 (0.84 to 1.27)</td>
<td>1.51 (1.27 to 1.78)</td>
<td></td>
</tr>
<tr>
<td>50–59</td>
<td>97.01 (95.13 to 98.93)</td>
<td>17.59 (16.80 to 18.42)</td>
<td>13.97 (13.26 to 14.71)</td>
<td>107.32 (105.34 to 109.34)</td>
<td>70.85 (69.24 to 72.49)</td>
<td>4.70 (4.29 to 5.13)</td>
<td>1.77 (1.53 to 2.05)</td>
<td>1.60 (1.37 to 1.86)</td>
<td></td>
</tr>
<tr>
<td>60–69</td>
<td>210.41 (207.28 to 213.58)</td>
<td>33.67 (32.42 to 34.95)</td>
<td>16.49 (15.62 to 17.39)</td>
<td>152.79 (150.12 to 155.49)</td>
<td>122.76 (120.37 to 125.18)</td>
<td>6.53 (5.99 to 7.11)</td>
<td>2.63 (2.29 to 3.01)</td>
<td>1.76 (1.49 to 2.08)</td>
<td></td>
</tr>
<tr>
<td>70–79</td>
<td>457.78 (451.84 to 463.79)</td>
<td>78.12 (75.67 to 80.62)</td>
<td>24.24 (22.88 to 25.65)</td>
<td>228.42 (224.22 to 232.67)</td>
<td>198.19 (194.28 to 202.15)</td>
<td>12.19 (11.23 to 13.20)</td>
<td>3.52 (3.02 to 4.09)</td>
<td>2.19 (1.79 to 2.64)</td>
<td></td>
</tr>
<tr>
<td>≥80</td>
<td>1127.67 (1115.77 to 1139.65)</td>
<td>181.74 (176.98 to 186.59)</td>
<td>41.59 (39.33 to 43.95)</td>
<td>344.83 (338.27 to 351.49)</td>
<td>274.19 (268.34 to 280.13)</td>
<td>23.31 (21.63 to 25.09)</td>
<td>5.32 (4.53 to 6.20)</td>
<td>2.04 (1.56 to 2.61)</td>
<td></td>
</tr>
<tr>
<td><strong>Females</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All ages</td>
<td>121.52 (120.38 to 122.67)</td>
<td>20.68 (20.21 to 21.16)</td>
<td>10.56 (10.23 to 10.90)</td>
<td>86.46 (85.50 to 87.43)</td>
<td>67.33 (66.48 to 68.18)</td>
<td>6.27 (6.01 to 6.53)</td>
<td>1.52 (1.40 to 1.66)</td>
<td>1.67 (1.54 to 1.81)</td>
<td></td>
</tr>
<tr>
<td>0–19</td>
<td>1.64 (1.36 to 1.95)</td>
<td>0.86 (0.66 to 1.10)</td>
<td>0.52 (0.37 to 0.70)</td>
<td>4.84 (4.36 to 5.36)</td>
<td>3.37 (2.97 to 3.81)</td>
<td>5.72 (5.20 to 6.29)</td>
<td>0.44 (0.30 to 0.61)</td>
<td>0.97 (0.76 to 1.21)</td>
<td></td>
</tr>
<tr>
<td>20–29</td>
<td>5.46 (4.82 to 6.17)</td>
<td>2.09 (1.70 to 2.54)</td>
<td>1.67 (1.32 to 2.08)</td>
<td>32.68 (31.07 to 34.35)</td>
<td>26.33 (24.89 to 27.84)</td>
<td>3.88 (3.34 to 4.48)</td>
<td>1.18 (0.89 to 1.53)</td>
<td>1.88 (1.51 to 2.31)</td>
<td></td>
</tr>
<tr>
<td>30–39</td>
<td>13.77 (12.74 to 14.87)</td>
<td>3.16 (2.68 to 3.71)</td>
<td>4.41 (3.83 to 5.05)</td>
<td>60.19 (58.00 to 62.44)</td>
<td>39.25 (37.48 to 41.07)</td>
<td>5.10 (4.48 to 5.79)</td>
<td>1.37 (1.06 to 1.75)</td>
<td>2.15 (1.75 to 2.61)</td>
<td></td>
</tr>
<tr>
<td>40–49</td>
<td>30.84 (29.28 to 32.46)</td>
<td>6.24 (5.55 to 6.99)</td>
<td>8.53 (7.72 to 9.40)</td>
<td>80.35 (77.83 to 82.94)</td>
<td>47.06 (45.13 to 49.05)</td>
<td>4.31 (3.74 to 4.94)</td>
<td>1.01 (0.74 to 1.34)</td>
<td>1.93 (1.56 to 2.37)</td>
<td></td>
</tr>
<tr>
<td>50–59</td>
<td>71.20 (68.93 to 73.53)</td>
<td>14.33 (13.32 to 15.40)</td>
<td>15.56 (14.51 to 16.67)</td>
<td>90.50 (87.93 to 93.11)</td>
<td>63.81 (61.66 to 66.01)</td>
<td>4.89 (4.30 to 5.52)</td>
<td>1.61 (1.28 to 1.99)</td>
<td>1.42 (1.11 to 1.78)</td>
<td></td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>Table 1</th>
<th>Incidence per 100 000 population (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age group, years</strong></td>
<td><strong>Ischaemic stroke</strong></td>
</tr>
<tr>
<td>0–19</td>
<td>1.91 (1.61 to 2.24)</td>
</tr>
<tr>
<td>20–29</td>
<td>3.96 (3.43 to 4.55)</td>
</tr>
<tr>
<td>30–39</td>
<td>12.36 (11.37 to 13.41)</td>
</tr>
<tr>
<td>40–49</td>
<td>43.19 (41.31 to 45.14)</td>
</tr>
<tr>
<td>50–59</td>
<td>123.18 (120.17 to 126.25)</td>
</tr>
<tr>
<td>60–69</td>
<td>270.67 (265.55 to 275.86)</td>
</tr>
<tr>
<td>70–79</td>
<td>539.40 (529.95 to 548.98)</td>
</tr>
<tr>
<td>≥80</td>
<td>1152.87 (1133.77 to 1172.22)</td>
</tr>
</tbody>
</table>
Table 2  Background rates of hospitalisations and emergency department visits for selected thromboembolic and coagulation disorders for both sexes and all ages combined in Ontario, 2015–2020

<table>
<thead>
<tr>
<th>Year</th>
<th>Incidence per 100 000 population (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ischaemic stroke</td>
</tr>
<tr>
<td>2015</td>
<td>124.75 (122.88 to 126.63)</td>
</tr>
<tr>
<td>2016</td>
<td>126.89 (125.03 to 128.78)</td>
</tr>
<tr>
<td>2017</td>
<td>126.87 (125.02 to 128.75)</td>
</tr>
<tr>
<td>2018</td>
<td>127.31 (125.47 to 129.17)</td>
</tr>
<tr>
<td>2019</td>
<td>129.39 (127.55 to 131.26)</td>
</tr>
<tr>
<td>2020</td>
<td>119.63 (117.88 to 121.41)</td>
</tr>
</tbody>
</table>

distribution of risk factors, and diagnostic and coding practices.

Despite the limitations, our estimated background rates of hospitalisations and emergency department visits for the selected thromboembolic and coagulation disorders will help contextualise any observed apparent increase in these potential AESI in relation to Canada’s mass COVID-19 immunisation programme. This will facilitate the identification of potential safety signals and help maintain vaccine confidence by preventing misinterpretation of expected baseline event rates.

Author affiliations
1Dalila Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
2ICES, Toronto, Ontario, Canada
3Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada
4School of Public Health, University of Alberta, Edmonton, Alberta, Canada
5Vaccine and Drug Evaluation Centre, Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
6Department of Medicine, McMaster University, Hamilton, Ontario, Canada
7Division of Neurology, The University of British Columbia, Vancouver, Columbia, Canada
8Stanford Stroke Center, Palo Alto, California, USA
9Immunization and vaccine-preventable diseases, Public Health Ontario, Toronto, Ontario, Canada

Twitter Shannon E MacDonald @SE_MacDonald, Thalia S Field @VancouverStroke and Jeffrey C Kwong @DrJeffKwong

Contributors JCK conceived of the study and oversaw the study. JCK, SN, MS and AJC designed the study. AJC prepared the data and performed the statistical analysis. SN conducted background literature review and drafted the manuscript. SN, AJC, MS, SEM, CR, MP, TF, LW, SEW and JCK interpreted the results, critically reviewed and edited the manuscript, approved the final version and agreed to be accountable for all aspects of the work. JCK is the guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding This work was supported by the Canadian Immunisation Research Network (CIRN) through a grant from the Public Health Agency of Canada and the Canadian Institutes of Health Research (CIHR). This study was also supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and Ministry of Long Term Care (MLTC) (Grant/award number: not applicable). JCK is supported by Clinician-Scientist Award from the University of Toronto Department of Family and Community Medicine.

Disclaimer The analyses, conclusions, opinions and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources; no endorsement is intended or should be inferred.

Competing interests ‘Yes, there are competing interests for one or more authors and I have provided a Competing Interests statement in my manuscript and in the box below’

Patient consent for publication Not applicable.

Ethics approval This study involves human participants but was not approved by ICES as a prescribed entity under Ontario’s Personal Health Information Protection Act (PHIPA). Section 45 of PHIPA authorises ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or for planning for all or part of the health system. Projects that use data collected by ICES under section 45 of PHIPA, and use no other data, are exempt from ICES’s Privacy and Legal Office. ICES is a prescribed entity under Ontario’s Personal Health Information Protection Act (PHIPA). Section 45 of PHIPA authorises ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or for planning for all or part of the health system. Projects that use data collected by ICES under section 45 of PHIPA, and use no other data, are exempt from

Research Ethics Board review. The use of the data in this project is authorised under section 45 and approved by ICES’ Privacy and Legal Office.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available. The dataset from this study is held securely in coded form at ICES. While legal data sharing agreements between ICES and data providers (eg, healthcare organizations and government) prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS (email: das@ices.on.ca). The full dataset creation plan and underlying analytic code are available from the authors on request, understanding that the computer programs may rely upon coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

ORCID iDs Sharpia Nasreen http://orcid.org/0000-0002-9793-113X
Shannon E MacDonald http://orcid.org/0000-0003-4675-4433
Jeffrey C Kwong http://orcid.org/0000-0002-7820-2046

REFERENCES
10 National Advisory Committee on Immunization (NACI). Recommendations on the use of COVID-19 vaccines. Ottawa, ON:

11 International statistical classification of diseases and related health problems. tenth revision, Canada (ICD-10-CA) 2018. Ottawa, Ontario, Canada: Canadian Institute for health information


16 Handley JD, Emsley HC. Validation of ICD-10 codes shows intracranial venous thrombosis incidence to be higher than previously reported. Health Inf Manag 2020;49:58–61.


